Barrier Disruption Stimulates Interleukin-1 Alpha Expression and Release from a Pre-formed Pool in Murine Epidermis
Overview
Affiliations
Previous studies have shown that barrier disruption increases epidermal mRNA levels of interleukin-1 alpha (IL-1 alpha). We used immunohistochemistry to examine IL-1 alpha expression in hairless mouse skin under basal conditions and following barrier abrogation. In untreated mice, IL-1 alpha was present in the dermis and nucleated epidermal layers in a diffuse, generalized pattern. In essential fatty acid deficient mice IL-1 alpha was present in all epidermal layers and the dermis, with prominent staining in the stratum corneum. After acute barrier disruption with tape-stripping, IL-1 alpha increased in the epidermis and dermis within 10 min, remained elevated at 2 and 4 h, and decreased to near basal levels by 24 h. Moreover, intense, perinuclear, basal cell staining appeared at 10 min, persisting until 4 h after barrier disruption. Since the increase in IL-1 alpha immunostaining after acute barrier abrogation precedes the increase in mRNA, we hypothesized that the IL-1 alpha might derive from a pre-formed pool. Prolonged occlusion of normal skin, a treatment that specifically reduces epidermal mRNA levels of IL-1 alpha, decreased basal immunostaining for IL-1 alpha and blunted the increase in IL-1 alpha usually seen following barrier disruption. Moreover, tape-stripping of skin, maintained ex vivo at 4 degrees C, resulted in increased IL-1 alpha immunostaining within the upper nucleated epidermal layers, as well as release of mature IL-1 alpha into the medium, as measured by Western blotting and enzyme-linked immunosorbent assay. In addition, the stratum corneum attached to the tape contained IL-1 alpha. These studies show that acute barrier disruption induces both the immediate release and dispersion of IL-1 alpha from a pre-formed, epidermal pool, as well as increased IL-1 alpha synthesis; both mechanisms are consistent with a role for IL-1 alpha in the regulation of proinflammatory and homeostatic processes in the skin.
Atopic Dermatitis: Pathophysiology.
Boothe W, Tarbox J, Tarbox M Adv Exp Med Biol. 2024; 1447:21-35.
PMID: 38724781 DOI: 10.1007/978-3-031-54513-9_3.
Lee Y, Ji B, Pae H, Cheon M, Xu G, Chun H Int J Mol Sci. 2024; 25(2).
PMID: 38255849 PMC: 10815266. DOI: 10.3390/ijms25020775.
Benefits of topical natural ingredients in epidermal permeability barrier.
Lei D, Liu D, Zhang J, Zhang L, Man M Front Physiol. 2024; 14:1275506.
PMID: 38239888 PMC: 10794395. DOI: 10.3389/fphys.2023.1275506.
Recent advances in epicutaneous immunotherapy and potential applications in food allergy.
Herve P, Dioszeghy V, Matthews K, Bee K, Campbell D, Sampson H Front Allergy. 2023; 4:1290003.
PMID: 37965375 PMC: 10641725. DOI: 10.3389/falgy.2023.1290003.
Effect of (Maxim.) Trautv extract on a model of atopic dermatitis in HaCaT cells and mice.
Bak S, Lim H, Won Y, Park E, Kim Y, Lee S Food Sci Nutr. 2023; 11(10):6616-6625.
PMID: 37823139 PMC: 10563673. DOI: 10.1002/fsn3.3610.